Your browser is no longer supported. Please, upgrade your browser.
SAGE Sage Therapeutics, Inc. daily Stock Chart
SAGE [NASD]
Sage Therapeutics, Inc.
Index- P/E- EPS (ttm)-11.80 Insider Own0.10% Shs Outstand51.93M Perf Week9.60%
Market Cap3.50B Forward P/E- EPS next Y-9.54 Insider Trans0.00% Shs Float51.00M Perf Month17.02%
Income-611.70M PEG- EPS next Q-2.39 Inst Own- Short Float12.18% Perf Quarter47.98%
Sales8.90M P/S393.18 EPS this Y-65.50% Inst Trans0.04% Short Ratio9.28 Perf Half Y96.99%
Book/sh14.25 P/B4.92 EPS next Y4.20% ROA-60.30% Target Price79.05 Perf Year-50.27%
Cash/sh15.15 P/C4.63 EPS next 5Y13.10% ROE-67.70% 52W Range25.01 - 155.33 Perf YTD-2.94%
Dividend- P/FCF- EPS past 5Y-51.60% ROI-75.00% 52W High-54.89% Beta2.47
Dividend %- Quick Ratio12.20 Sales past 5Y- Gross Margin92.90% 52W Low180.17% ATR3.15
Employees675 Current Ratio12.20 Sales Q/Q22.20% Oper. Margin- RSI (14)67.52 Volatility5.42% 5.05%
OptionableYes Debt/Eq0.00 EPS Q/Q20.00% Profit Margin- Rel Volume0.86 Prev Close69.72
ShortableYes LT Debt/Eq0.00 EarningsAug 10 AMC Payout- Avg Volume668.82K Price70.07
Recom1.90 SMA2011.52% SMA5023.06% SMA20042.88% Volume573,861 Change0.50%
Sep-11-20Upgrade Wedbush Neutral → Outperform
Aug-10-20Upgrade Raymond James Mkt Perform → Outperform $70
May-08-20Downgrade Wedbush Outperform → Neutral
Apr-08-20Downgrade Guggenheim Buy → Neutral
Mar-18-20Upgrade RBC Capital Mkts Sector Perform → Outperform $73 → $60
Mar-06-20Initiated Citigroup Buy $71
Feb-28-20Reiterated H.C. Wainwright Neutral $87 → $78
Feb-06-20Initiated Mizuho Neutral
Dec-06-19Reiterated RBC Capital Mkts Outperform $190 → $100
Dec-05-19Reiterated Guggenheim Buy $200 → $110
Dec-05-19Downgrade SunTrust Buy → Hold
Oct-30-19Initiated H.C. Wainwright Neutral $160
May-23-19Initiated Wedbush Outperform
Apr-25-19Initiated Jefferies Buy $195
Dec-14-18Initiated Wolfe Research Outperform
Oct-11-18Initiated Oppenheimer Outperform $170
Aug-07-18Reiterated Stifel Buy $198 → $239
Aug-06-18Initiated Piper Jaffray Overweight $206
Jun-06-18Initiated Ladenburg Thalmann Buy $230
Mar-26-18Resumed Canaccord Genuity Buy $210
Oct-19-20 05:00PM  
Oct-15-20 06:30AM  
Oct-01-20 07:00AM  
Sep-16-20 04:55PM  
Sep-15-20 09:56AM  
Sep-11-20 01:38PM  
09:38AM  
08:41AM  
Sep-10-20 06:30AM  
Sep-01-20 06:30AM  
Aug-20-20 04:31PM  
Aug-10-20 05:31PM  
07:20AM  
07:01AM  
06:30AM  
Jul-30-20 06:30AM  
Jul-21-20 06:30AM  
Jul-13-20 10:22AM  
Jun-24-20 03:58PM  
Jun-17-20 04:04PM  
Jun-10-20 08:37PM  
Jun-09-20 09:55AM  
Jun-01-20 06:30AM  
May-09-20 05:01PM  
May-08-20 06:30AM  
May-07-20 04:01PM  
May-03-20 07:30PM  
Apr-22-20 11:09AM  
Apr-21-20 07:39AM  
Apr-20-20 07:48AM  
Apr-16-20 06:30AM  
Apr-13-20 10:51AM  
Apr-08-20 12:29PM  
10:47AM  
07:53AM  
06:10AM  
06:09AM  
04:34AM  
Apr-07-20 04:01PM  
08:37AM  
Apr-03-20 04:30PM  
Mar-27-20 02:53PM  
Mar-20-20 08:30PM  
Mar-19-20 06:57PM  
Mar-18-20 06:30AM  
Mar-12-20 08:45AM  
Mar-11-20 07:00AM  
Mar-04-20 04:30PM  
Mar-02-20 09:59AM  
07:24AM  
Feb-27-20 07:39PM  
06:30AM  
Feb-26-20 08:31AM  
Feb-25-20 12:03PM  
Feb-24-20 06:30AM  
Feb-10-20 06:30AM  
Feb-04-20 04:30PM  
Feb-03-20 11:27AM  
Jan-17-20 08:40AM  
Jan-09-20 08:44AM  
Jan-03-20 04:30PM  
Dec-29-19 03:24AM  
Dec-23-19 02:47PM  
06:30AM  
Dec-19-19 03:07PM  
Dec-16-19 11:28AM  
Dec-14-19 02:56PM  
Dec-12-19 08:15PM  
10:38AM  
Dec-11-19 08:01PM  
09:41AM  
Dec-10-19 09:18PM  
07:30AM  
Dec-09-19 10:20AM  
06:20AM  
Dec-06-19 03:00PM  
09:30AM  
09:26AM  
Dec-05-19 08:31PM  
04:18PM  
04:05PM  
11:00AM  
10:24AM  
09:54AM  
09:42AM  
07:21AM  
07:18AM  
06:40AM  
06:30AM  
Dec-04-19 09:28AM  
Dec-03-19 04:30PM  
09:57AM  
Nov-25-19 06:44PM  
Nov-20-19 06:10PM  
Nov-15-19 10:02AM  
Nov-12-19 06:31AM  
Nov-11-19 04:30PM  
07:50AM  
Nov-05-19 06:00PM  
12:01PM  
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system (CNS) disorders. Its lead product candidate is ZULRESSO, a proprietary intravenous formulation of brexanolone for the treatment of postpartum depression (PPD). The company's product pipeline also includes SAGE-217, a novel neuroactive steroid, which is in Phase III clinical trials for treating PPD, major depressive disorders, bipolar depression, and generalized anxiety disorders; and SAGE-324, a novel compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epileptiform disorders and Parkinson's diseases. In addition, its product pipeline comprises SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which has completed Phase I clinical trial for the treatment of depression, Huntington's disease, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. Further, the company is developing SAGE-904, an oral therapy that is in Phase I clinical trial for disorders associated with NMDA hypofunction; and SAGE-689 for intramuscular administration. Sage Therapeutics, Inc. has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of SAGE-217 in Japan, Taiwan, and South Korea. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
IGUCHI KIMICFO & TreasurerApr 30Option Exercise1.364,0005,44033,261May 04 04:53 PM
IGUCHI KIMICFO & TreasurerDec 10Option Exercise1.3650068029,261Dec 10 09:26 PM
Robichaud AlbertChief Scientific OfficerDec 09Option Exercise20.1215,743316,746111,400Dec 10 08:04 PM
IGUCHI KIMICFO & TreasurerDec 09Option Exercise1.3615,00020,40028,761Dec 10 09:26 PM
JONAS JEFFREY MPresident & CEODec 09Buy64.207,500481,50054,530Dec 10 08:04 PM
Robichaud AlbertChief Scientific OfficerDec 09Buy64.1625,0001,604,000136,400Dec 10 08:04 PM